Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 6
1946 38
1947 58
1948 40
1949 97
1950 106
1951 81
1952 125
1953 106
1954 104
1955 126
1956 100
1957 133
1958 151
1959 163
1960 157
1961 147
1962 117
1963 144
1964 142
1965 159
1966 150
1967 160
1968 222
1969 225
1970 257
1971 288
1972 415
1973 481
1974 564
1975 470
1976 441
1977 512
1978 450
1979 416
1980 383
1981 355
1982 344
1983 346
1984 386
1985 319
1986 353
1987 321
1988 283
1989 359
1990 406
1991 377
1992 415
1993 414
1994 417
1995 401
1996 374
1997 431
1998 406
1999 546
2000 536
2001 425
2002 373
2003 426
2004 424
2005 410
2006 369
2007 383
2008 369
2009 355
2010 375
2011 351
2012 335
2013 352
2014 413
2015 433
2016 327
2017 276
2018 230
2019 295
2020 61
Text availability
Article attribute
Article type
Publication date

Search Results

22,195 results
Results by year
Filters applied: . Clear all
Page 1
Biomarkers for Homologous Recombination Deficiency in Cancer.
Hoppe MM, et al. J Natl Cancer Inst 2018 - Review. PMID 29788099
Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA repair pathway of clinical interest due to the sensitivity of homologous recombination-deficient cells to poly-ADP ribose polymerase (PARP) inhibitors. The measurement of homologous recombination deficiency (HRD) in cancer is therefore vital to the appropriate design of clinical trials incorporating PARP inhibitors. ...
Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA repair pathway of clinical interest due to the …
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Shimelis H, et al. J Natl Cancer Inst 2018. PMID 30099541 Free PMC article.
BACKGROUND: Germline genetic testing with hereditary cancer gene panels can identify women at increased risk of breast cancer. ...Associations between deleterious mutations in cancer predisposition genes and TNBC were evaluated using results from TNBC patients and reference controls. ...
BACKGROUND: Germline genetic testing with hereditary cancer gene panels can identify women at increased risk of breast cancer. …
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
Oh M, et al. J Natl Cancer Inst 2018. PMID 30380096
BACKGROUND: Investigations of the associations with colorectal cancer have yielded conflicting results. The aim of our study was to synthesize the research on colorectal cancer risks in BRCA mutation carriers by means of a systematic review and quantitatively by means of meta-analyses overall and in subgroups of BRCA mutation carriers. ...Unadjusted odds ratios (ORs) were used to derive pooled estimates of colorectal cancer risk overall and in subgroups defined by mutation type (BRCA1 or BRCA2), cancer type (colorectal or colon cancer), study design (age-sex-adjusted or crude), and ascertainment method (ascertained or inferred genotyping). ...
BACKGROUND: Investigations of the associations with colorectal cancer have yielded conflicting results. The aim of our study was to s …
Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole S, et al. J Natl Cancer Inst 2018 - Review. PMID 30517737 Free PMC article.
Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P < .001), mesothelioma (P < .001), cutaneous melanoma (P < .001), and nonmelanoma skin cancer (P < .001). ...
Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P < .001), mesothelio …
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer MJ, et al. J Natl Cancer Inst 2019 - Review. PMID 30859213
The pace of ADC development is accelerating, with the number of investigational agents in human trials having more than tripled over the past 5 years, underscoring the enthusiasm for this transformative approach to cancer treatment. ...
The pace of ADC development is accelerating, with the number of investigational agents in human trials having more than tripled over the pas …
Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis.
Yarmolinsky J, et al. J Natl Cancer Inst 2018. PMID 29788239 Free PMC article.
In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 μg/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade prostate cancer and type 2 diabetes. ...Our Mendelian randomization analyses do not support a role for selenium supplementation in prostate cancer prevention and suggest that supplementation could have adverse effects on risks of advanced prostate cancer and type 2 diabetes....
In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 μg/L increase in circu …
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
Sauerbrei W, et al. J Natl Cancer Inst 2018 - Review. PMID 29873743 Free PMC article.
Despite support for REMARK from major cancer journals, prognostic factor research studies remain poorly reported. To encourage dissemination and uptake of REMARK, we have produced this considerably abridged version of the detailed explanatory manuscript, which may also serve as a brief guide to key issues for investigators planning tumor marker prognostic studies. ...
Despite support for REMARK from major cancer journals, prognostic factor research studies remain poorly reported. To encourage dissem …
Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
Carreira H, et al. J Natl Cancer Inst 2018. PMID 30403799 Free PMC article.
BACKGROUND: We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors (≥1 year) compared with women with no history of cancer. ...CONCLUSIONS: There is compelling evidence of an increased risk of anxiety, depression and suicide, and neurocognitive and sexual dysfunctions in breast cancer survivors compared with women with no prior cancer. ...
BACKGROUND: We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors (≥1 year) com …
Methylation-Based Biological Age and Breast Cancer Risk.
Kresovich JK, et al. J Natl Cancer Inst 2019. PMID 30794318 Free PMC article.
We tested this hypothesis for breast cancer. METHODS: Using a case-cohort approach, we measured baseline blood DNA methylation of 2764 women enrolled in the Sister Study, 1566 of whom subsequently developed breast cancer after an average of 6 years. ...Case-only analysis suggested that, among women who develop breast cancer, increased age acceleration is associated with invasive cancer (odds ratio for invasive = 1.09, 95% CI = 0.98 to 1.22, P = .10). ...
We tested this hypothesis for breast cancer. METHODS: Using a case-cohort approach, we measured baseline blood DNA methylation of 276 …
Response
Tibau A, et al. J Natl Cancer Inst 2018. PMID 29529214
22,195 results
Jump to page
Feedback